New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Future Oncology - Technology, Products, Markets, and Service Opportunities

* Requires Adobe Acrobat Reader

FUTURE ONCOLOGY - TECHNOLOGY, PRODUCTS, MARKETS, AND SERVICE OPPORTUNITIES IN THE CANCER FIELD

FUTURE ONCOLOGY
Volume 8 #3 January 2005


STATE-OF-THE-ART IN THE MANAGEMENT OF CANCER

PANCREATIC CANCER PART V
ANGIOGENESIS INHIBITORS/ANTIMETASTATIC AGENTS AND TARGETED DELIVERY/GENE TRANSFER APPROACHES

ANGIOGENESIS INHIBITORS/ANTIMETASTATIC AGENTS
  • Endothelial Monocyte-activating Protein II (IMAP-II)
  • Matrix Metalloproteinase Inhibitors
    • BAY 12-9566
    • Marimastat
    • MMI-166
    • Ro28-2653
  • Vascular Endothelial Growth Factor (VEGF) Inhibitors
    • 2C3
    • Bevacizumab
    • CEP-7055
    • CX-3543
    • E7080
    • IMC-1121b
    • Sorafenib
    • SU6668
    • ZD6474
  • Urokinase Plasminogen Activator (uPA) System Inhibitors
    • WX-UK1
    • WX-671
  • Other Antiangiogenesis Agents
    • CNTO 859
    • Proteinase-activated receptor-2 (PAr2) inhibitor 547m
    • Thalidomide analogs
    • Volociximab
  • Other Antimetastatic Agents
    • Anti-ephA2 and anti-ephA4 MAb
    • AZM475271
    • GCS100 and GCS100LE
    • Human aspartyl (asparaginyl) -hydroxylase (HAAH) inhibitors
    • MAb K931

TARGETED DRUG DELIVERY

  • Targeted Toxins
    • AS1406
    • SS1P [SS1(dsFv)-PE38, SS1-PE38]
    • TST10088 and TST1000
  • Radioimmunoconjugates
    • IMMU-107
    • Labetuzumab
    • XR303
    • YM-1001
  • Targeted Cytotoxics
    • AN-238 and AN-162
    • Glufosfamide
  • Gene Transfer
    • Recombinant adenovirus NK4 (Ad-NK4)
    • Rexin-G
    • TNFerade
  • Oncolytic Viruses
    • CG5757
    • Reolysin


LIST OF EXHIBITS

Exhibit 1 - Novel Targeted Therapeutics Evaluated either Clinically or Preclinically for the Treatment of Pancreatic Cancer

Exhibit 2 - Selected Targets of Antiangiogenesis Inhibitors/Antimetastasis Agents and Drug Delivery/Gene Transfer Approaches for Treatment of PDAC

Exhibit 3 - Ongoing Combination Clinical Trials with Bevacizumab in PDAC


HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887